Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Large Pragmatic RCT Investigating Treatment Versus Non Treatment of Low-risk BCCs in Elderly
Authors not listed
University Hospital, Ghent · 2021
Abstract
This study will be a randomized controlled trial (RCT). Patients with a minimum age of 75 years who consult at the dermatology department of the Ghent University Hospital and who are diagnosed with minimum one lesion suspicious for a low-risk basal cell carcinoma will be asked to participate in this study.
Rationale: Basal cell carcinomas (BCCs) represent 70% of all skin cancers. These tumors do not metastasize but are locally invasive if left untreated. There is a high incidence of BCC in elderly and clinicians frequently face important treatment dilemmas. The approach to BCC in elderly should be investigated thoroughly, since current data on health-related quality of life, complication risks and biological behavior of these tumors is absent, and most guidelines are based on studies in young patients.
Objective: The investigators will examine the possibility of not treating all BCCs by collecting data on the in vivo biological behavior of low-risk basal cell carcinomas in elderly patients with state-of-the-art imaging techniques. The investigators want to combine tumor characteristics with patient profiles, in order to estimate whether a chosen treatment will positively affect the patients' quality of life within a predetermined timeframe.
Study design: Randomized controlled trial (RCT) with study visits every 6 to 12 months for a total follow-up period of 36 months.
Study population: Patients consulting at the Department of Dermatology of the Ghent University Hospital with the minimum age of 75 years and a new diagnosis of (a) low-risk basal cell carcinoma(s).
Intervention: Evaluation of the impact on the quality of life and the complication risks in both study arms. In addition, survival data will be gathered in both study arms. In the non-treatment arm, there will be an evaluation of the biological behavior of these low-risk basal cell carcinomas using in vivo imaging devices.
Patients in the treatment arm will receive standard care. Patients in the non-treatment arm will be closely monitored: the tumor will be evaluated using non-invasive imaging devices. Patients will be asked to fill in a questionnaire concerning their HrQoL at consecutive time points. Also patient-reported side effects will be evaluated via a questionnaire. The investigators will compare standard treatment versus non-treatment (1:1 allocation) in a randomized controlled trial.
Subjects can withdraw from participating in this study at any time for any reason without any consequences.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-14 MST
Cite this
APA
Anonymous. (2021). A Large Pragmatic RCT Investigating Treatment Versus Non Treatment of Low-risk BCCs in Elderly. <em>University Hospital, Ghent</em>. https://clinicaltrials.gov/study/NCT05110924
Vancouver
Anonymous. A Large Pragmatic RCT Investigating Treatment Versus Non Treatment of Low-risk BCCs in Elderly. University Hospital, Ghent. 2021.
BibTeX
@misc{anon2021ALarge,
title = {A Large Pragmatic RCT Investigating Treatment Versus Non Treatment of Low-risk BCCs in Elderly},
author = {Anonymous},
journal = {University Hospital, Ghent},
year = {2021},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Hospital de Clinicas de Porto Alegre 2024
Open access · US-GOV
The Impact of Geriatric Assessment on the Treatment Plan of Elderly Patients With Type 2 Diabetes Mellitus: a Randomized Clinical Trial.
Parc de Salut Mar 2019
Open access · US-GOV
The Impact of Frailty on the Postoperative Outcomes of Gastric Cancer Surgery
Cancer Medicine 2023
Open access · CC-BY
Association between PD ‐1 inhibitor‐related adverse events and frailty assessed by frailty index in lung cancer patients
Clinical Epigenetics 2026
Open access · CC-BY
Exploring a targeted epigenetic clock based on mortality-associated CpGs as a potential biomarker for frailty
Clinical epigenetics 2026
Open access · OA
Exploring a targeted epigenetic clock based on mortality-associated CpGs as a potential biomarker for frailty.
Chang Gung Memorial Hospital 2025
Open access · US-GOV